Integrum’s expansion in US continues with new Osseointegration Center at Emory Healthcare, Georgia
Patients at Emory Healthcare now have access to the OPRA™ Implant system for above-knee amputations.
Emory Healthcare, the largest healthcare system in the state of Georgia with 11 hospitals and 250 provider locations, has launched a new Osseointegration Program with Integrum’s OPRA™ Implant System. The program is led by Nickolas Reimer, MD, and Shervin Oskouei, MD, specialists in orthopaedic oncology and orthopaedic surgery.
Integrum’s OPRA™ Implant System is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ Implant System consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur, and after a healing time of several months, the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.
“We’re excited to introduce this new technology to our patients to advance their limb function and improve their quality of life,” says Scott D. Boden, MD, vice president for business innovation for Emory Healthcare and professor and chair of the Department of Orthopaedics, Emory University School of Medicine.
Over the past years, the introduction and consideration of osseointegration as a viable option for specific amputees within the limb loss community has continued to establish itself in the U.S. market. This rapidly developing treatment for amputee care gained a considerable boost when the FDA awarded Integrum an HDE approval for the OPRA™ Implant System in July 2015. The subsequent years have seen the Department of Defense, University of California San Francisco, Johns Hopkins Hospital, and Presbyterian St.Luke’s Medical Center Hospital adopt the OPRA™ Implant System.
Blake Pokress, Vice President of Integrum Inc added, “We are excited to see Emory Healthcare adopt our technology through our partners at Onkos Surgical. We strive to make this remarkable technology accessible for individuals living with limb loss in the United States, and this is another step towards that”.
To make an appointment at Emory Orthopaedics & Spine Center, call 404-778-3350.
The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 14:30 CET on August 26th, 2020.Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company´s Certified Adviser.
For further information, please contact:Maria Lopez, CEO
Cell: 0708-46 10 69
Email: maria.lopez@integrum.se
Blake Pokress, VP North America
Cell: +1-650-862-9302
Email: blake.pokress@integrum.se
Certified Adviser:
Erik Penser Bank AB
Tel. +46 8 463 8000
certifiedadviser@penser.se
About Integrum
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco, CA. Since 1990 osseointegration, the science behind the OPRA™ Implant System, has been helping individuals with amputations towards an improved quality of life. Thorough surgical experience gained over almost three decades from 500 surgeries in 13 countries has led to the development of Integrum’s system for bone-anchored prosthetics – a beneficial alternative to the traditionally used socket prosthesis. Integrum’s OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2015 for use in the U.S. under a Humanitarian Use Device (HUD) designation which was reviewed through the Humanitarian Device Exemption (HDE) pathway. The OPRA™ Implant System is the only FDA approved technology for above knee, bone anchored prosthetics available in the U.S. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.
Tags:
